IQWiG rejects Cell Therapeutics' Pixuvri PMLiVE Results from the PIX306 trial, comparing Pixuvri and Roche's MabThera (rituximab) to a regimen of Lilly's Gemzar (gemcitabine) and MabThera, are expected by June 2015 as part of this post-marketing follow-up. Conditional marketing authorisations are ... |
